Rapid growth of branded drugs will slow from 2022 onward due to the market entry of generics.
By Louisa Joseph, Analyst
25 March 2016
Datamonitor Healthcare forecasts that the value of the branded drugs currently approved for stroke prevention in atrial fibrillation (SPAF) will experience rapid growth during the forecast period.
Datamonitor Healthcare surveyed 233 cardiologists across the US, Japan, and five major EU markets (France, Germany, Italy, Spain, and the UK) to calculate the SPAF treatment population and to gain an understanding of current and future prescribing patterns in SPAF.
The combination of a rise in physician acceptance of the novel oral anticoagulant (NOAC) class and the approval of antidotes to these drugs will lead to strong growth within the SPAF market. Datamonitor Healthcare estimates that the SPAF market will grow at a compound annual growth rate (CAGR) of 5.69% over 2015–24.
The approval of andexanet alfa (Portola Pharmaceuticals) as an antidote for Xarelto (rivaroxaban; Bayer/Johnson & Johnson), Eliquis (apixaban; Bristol-Myers Squibb/Pfizer), and Savaysa (edoxaban; Daiichi Sankyo), and the introduction of Praxbind (idarucizumab; Boehringer Ingelheim) as an antidote for Pradaxa (dabigatran; Boehringer Ingelheim) will help to ensure patient safety and increase physician acceptance of these anticoagulants over the forecast period. The entrance of less expensive generic versions of Pradaxa and Xarelto will reduce the growth in the value of the SPAF market from 2022 onward.
Stroke Prevention in Atrial Fibrillation market forecast in the US ($m), 2015–2018
Source: Datamonitor Healthcare’s SPAF forecast, March 2016
Datamonitor Healthcare’s SPAF forecast covers the expected impact of the novel oral anticoagulant drug class on the SPAF market.
Get your free demo today – simply submit the form to the right.